Current News

Print version | PDF version | Send article | RSS-Feed

Antisoma and Raylo sign major manufacturing deal for AS1411

15 Mar 2005 - Cancer drug developer Antisoma plc announced that it has signed an agreement with Raylo Chemicals of Edmonton, Alberta, Canada, for the manufacture of AS1411 (formerly AGRO100). Quantities produced will be amongst the largest to date for any aptamer drug, and sufficient to support multiple clinical trials. Antisoma is planning a programme of trials to evaluate thoroughly the efficacy of AS1411, building on promising signs of anti-cancer activity seen in a phase I study conducted at the Brown Cancer Center in Louisville, Kentucky, USA.
 
Raylo, a subsidiary of Degussa, has considerable expertise in the production of aptamers and other oligonucleotide drugs, having been involved in the manufacture of Pfizer and Eyetech's Macugen, the first aptamer drug to gain FDA approval.